Publication

[Science] Investigators established FOXA1 as a multifaceted oncogene, with distinct mutational classes divergently evolving to drive prostate tumorigenesis or therapy-resistant progression.

[Nature Cancer] Researchers showed that Pten deletion in basal cells led to distinct cell fate reprogramming and tumor initiation in a regionalized manner.

[Molecular Cell] Scientists demonstrated that dysregulated ubiquitination and turnover by the cullin 3^ZBTB2 E3 ligase complex induce the upregulation of the short isoform of nuclear-receptor-binding SET domain protein 3, which confers PARPi resistance in prostate cancer cells and patient-derivedmetastatic castration-resistant prostate cancer samples.

[Small Methods] Scientists introduced PruEV-AI, an integrated diagnostic system that combines rapid urinary extracellular vesicles isolation with AI-based biomarker analysis.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators supported the feasibility of using clinical metabolic imaging techniques as adjunctive tools for improving cribriform prostate cancer detection in clinical practice, with prospective studies in larger cohorts warranted to obtain definitive results.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists demonstrated the feasibility of using predicted structural models for optimizing lead compounds, and HEAL-116 provides a promising avenue for the clinical validation of 3βHSD1 inhibitors in prostate cancer therapy.